Journey Medical Corp. (DERM), a commercial-stage pharmaceutical company that focuses on the treatment of dermatological conditions, is approaching a key regulatory milestone next month that should be closely monitored.
The company's investigational drug, DFD-29, proposed for the treatment of inflammatory lesions and erythema of rosacea in adults, is under FDA review, with a decision due on November 4, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com